作者
Osama Mosalem, Mark Mujer, Fawzi Abu Rous, Craig E Cole
发表日期
2020/11/5
期刊
Blood
卷号
136
页码范围
20
出版商
Content Repository Only!
简介
Background:
Aspagarinase is a fundamental component for the treatment of patients with acute lymphoblastic leukemia (ALL). Venous thromboembolism (VTE) is a known complication of asparaginase therapy during treatment for ALL. This is attributed to the depletion of anticoagulants, particularly acquired antithrombin deficiency following asparaginase administration. The incidence of thrombosis following asparaginase is more prevalent in adults versus children and is estimated to be around 5-35 % and 2.4-8% respectively. Multiple studies have investigated the efficacy and safety of antithrombin supplementation. The recent THROMBOTECT study showed that prophylactic use of antithrombin (AT) or low molecular weight heparin (LMWH) is associated with significant risk reduction of thromboembolism in children and adolescents during induction chemotherapy of ALL. Our study sought to review the cohort …
学术搜索中的文章
O Mosalem, M Mujer, FA Rous, CE Cole - Blood, 2020